Abstract
Bronchopulmonary dysplasia (BPD) is associated with significant short- and long-term morbidity in preterm infants, and it can be prevented in some infants with vitamin A prophylaxis. Vitamin A, once widely used in neonatal intensive care, was scarce for the last few years, but has become available again at a much higher price, leading to dilemmas about its routine use. In this review we discuss experimental, clinical and socioeconomic evidence related to BPD, and provide a framework for clinicians and policy-makers to evaluate the value of vitamin A treatment and make decisions about its use for prevention of BPD.
| Original language | English |
|---|---|
| Pages (from-to) | 581-585 |
| Number of pages | 5 |
| Journal | Journal of Perinatology |
| Volume | 36 |
| Issue number | 8 |
| DOIs | |
| State | Published - 1 Aug 2016 |
| Externally published | Yes |
Fingerprint
Dive into the research topics of 'Should we still use Vitamin A to prevent bronchopulmonary dysplasia?'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver